AAAPC Announces Educational Webinar for AMA Credit on the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AAAPC Announces Educational Webinar for AMA Credit on the Safety of SCIT-Based Allergen-Immunotherapy

NEW YORK, Oct. 17, 2016 (GLOBE NEWSWIRE) -- The Academy of Allergy and Asthma in Primary Care ( AAAPC ) will host a live educational webinar on Monday, October 24 from 1:00 p.m. – 2:00 p.m. ET about "The Safety of SCIT-Based Allergen-Immunotherapy." The webinar will be presented by allergist-immunologist Dr. Frederick Schaffer, who will discuss safe practices when it comes to subcutaneous immunotherapy (SCIT) and related morbidity and mortality risks, as well as how to minimize these risks in patients. A question-and-answer session will immediately follow the presentation.

Attendees will gain an understanding not only of safe practices, but of safe patient selection, as well as a delineation of therapeutic-based risks in order to best assess and treat patients with allergic disorders while facilitating long term patient safety. As a result, attendees are able to fulfill AMA PRA Credits for learning patient selection, how to minimize morbidity and how to promote safety based compliance for patients on SCIT.

Learning Objectives: 

  • Determine who is an appropriate patient for safe diagnostic assessment and treatment
  • Discuss the safety profile of several therapeutic regimens discussed
  • Describe how adverse events, safety, and compliance determination impact the efficacy of therapy
  • Utilize safety assessment tools to utilize throughout the 3 year course of SCIT therapy

WHAT: "The Safety of SCIT-Based Allergen-Immunotherapy"

WHEN: Monday, October 24, 2016, 1:00 p.m. ET

REGISTER: For details and registration, visit https://www.aaapc.org/i4a/pages/index.cfm?pageID=3352

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Amedco and AAAPC. Amdeco is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Amedco designates this live activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Academy of Allergy and Asthma in Primary Care (AAAPC) is a national non-profit organization, which supports innovative care models of allergy and asthma care in the primary care setting and assists physicians in expanding their role to provide allergy diagnostics and therapy to the under-served patient population. AAAPC is a voice for thousands of physicians and patients using allergy and asthma diagnostic and therapeutic services to raise awareness of the link between allergy care and asthma prevention, particularly in pediatric and family practice populations.

The mission of the Academy of Allergy & Asthma in Primary Care is to foster the ability of physicians to provide high quality, accessible patient diagnostic and therapeutic allergy and asthma care.

Kristen Kurtz T: 917-561-2406 E:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Insider Selling in PaySign: What It Means

Updated Category News Views 140

Matthew Lanford's Insider Sale: Key Insights Matthew Lanford, who serves as the Chief Payments Officer at PaySign, recently made headlines by disclosing an insider sale. This transaction was reported to the SEC, where Lanford sold a total of 26,367 shares, valued at approximately $186,812. This event raises eyebrows and invites further scrutiny from investors and market...

Continue Reading
Innovative Therapies for Chronic Heart Failure on the Rise

Updated Category News Views 169

Understanding Chronic Heart Failure and Its Challenges Chronic heart failure (CHF) is a serious condition where the heart struggles to pump blood efficiently, causing significant health issues. This condition affects numerous individuals across the globe, especially in aging populations. As people age, they become increasingly vulnerable, with CHF incidence becoming...

Continue Reading
International Paper Achieves Environmental Milestone

Updated Category News Views 226

International Paper Achieves a Milestone in Sustainability International Paper (NYSE: IP), a leader in sustainable packaging, has recently announced a significant achievement in its environmental efforts. The company has successfully conserved and restored over one million acres of ecologically important forestland, well ahead of its scheduled targets. This remarkable...

Continue Reading
Navitas and NVIDIA Team Up for Advanced 800 V Power Solutions

Updated Category News Views 450

Navitas Partners with NVIDIA for Cutting-Edge Power Solutions Navitas Semiconductor, recognized as a front-runner in power semiconductor technologies, has taken a monumental leap by teaming up with NVIDIA to innovate the next generation of 800 V high voltage direct current (HVDC) architecture. This partnership aims to meet the increasing power demands in data centers that...

Continue Reading
Innventure, Inc. Anticipates Strong Fourth Quarter Results

Updated Category News Views 199

Exciting Times for Innventure, Inc. As we approach the end of the fiscal year, anticipation builds around Innventure, Inc. (NASDAQ: INV). This innovative company has carved out its niche as a technology commercialization platform, setting the stage for considerable developments and announcements. The excitement is palpable as stakeholders and investors are gearing up for...

Continue Reading